Weiss, Robert - In: Health economics review 12 (2022) 1, pp. 1-12
-10 million Americans at risk for recurrent cellulitis. Without convincing predictions of the costs and benefits of lymphedema … treatment, insurers are reluctant to fully cover treatment of this common condition. Earlier papers discussed the costs and … benefits of the first 5, 7, and 10 years of a lymphedema treatment mandate in Virginia. This paper updates these costs and …